$3.46-1.8%Nov 13 close
Reported results on November 11, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 11, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $5.7M | $0.00 | — |
| Profit | -$13.9M | -$31.2M | +55.43% |
| Profit per share | -$0.14 | -$0.41 | +65.85% |
| Free Cash Flow | -$15.6M | -$26.1M | +40.32% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Prelude Therapeutics Inc reported on November 11, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and JAK2V617F mutant selective inhibitors -- new approaches to clinically validated targets with transformative potential for patients. We are leveraging our expertise in targeted protein degradation to create and develop next generation degrader antibody conjugates (DACs) with novel payloads. We are on a mission to extend the promise of precision medicine to every cancer patient in need.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Prelude Therapeutics Inc’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.